Dyne Therapeutics(DYN) - 2024 Q4 - Annual Report

Financial Performance - For the year ended December 31, 2024, the company reported a net loss of $317.4 million, compared to a net loss of$235.9 million for 2023, representing an increase in loss of $81.5 million[647]. - As of December 31, 2024, the company had an accumulated deficit of$949.9 million[647]. - Net cash used in operating activities was $292.4 million in 2024, compared to$188.2 million in 2023, indicating a 55.5% increase in cash outflow[680]. - Interest income for 2024 was $26.9 million, up from$7.6 million in 2023, reflecting a significant increase due to higher cash balances[668]. - Net cash provided by financing activities reached $809.9 million in 2024, a substantial increase from$54.3 million in 2023[682]. Expenses - Research and development expenses for 2024 were $281.4 million, up from$210.8 million in 2023, reflecting an increase of $70.6 million[663]. - General and administrative expenses increased to$62.5 million in 2024 from $31.4 million in 2023, a rise of$31.1 million[663]. - The total operating expenses for 2024 were $343.9 million, compared to$242.2 million in 2023, marking an increase of $101.7 million[663]. - Research and development expenses for DYNE-101 rose to$74.1 million in 2024 from $67.1 million in 2023, a 10.5$90.5 million[664][665]. - General and administrative expenses surged to $62.5 million in 2024 from$31.4 million in 2023, marking a 99.5% increase[667]. - The company expects to incur significant expenses related to developing commercialization capabilities if any product candidates are approved[648]. - The company anticipates increased expenses related to ongoing clinical development of product candidates DYNE-101 and DYNE-251[685]. Cash and Funding - As of December 31, 2024, the company had cash, cash equivalents, and marketable securities totaling $642.3 million[672]. - The company believes its existing cash and marketable securities will fund operations into the second half of 2026[651]. - The company expects to fund its operating expenses into the second half of 2026 based on current cash reserves and projections[686]. - The company issued 3,800,465 shares of common stock in 2024, generating net proceeds of$97.9 million at an average price of $26.86 per share[675]. Agreements and Obligations - The company has entered into a license agreement with the University of Mons, with payment obligations contingent upon achieving specified development, regulatory, and commercial milestones[690]. - A lease agreement for office and laboratory space has been established, with a base rent obligation starting at$0.4 million per month, increasing to $0.5 million per month over the lease term[691]. - A master manufacturing services agreement has been signed with a CMO, obligating the company to compensate the CMO at least$60 million for production through 2026[692]. Accounting Policies - The company emphasizes the importance of accrued research and development expenses as a critical accounting policy, which is expected to have a material impact on financial condition and results of operations[694]. - The company estimates accrued research and development expenses based on contracts and service provider communications, with no material differences reported to date between estimates and actual incurred amounts[696]. - Stock-based compensation is measured using the Black-Scholes option-pricing model, with expenses recognized over the requisite service period[697]. Risk Factors - The investment portfolio includes cash, cash equivalents, and marketable securities, with no material impact from interest rate changes reported for the years ended December 31, 2024, 2023, and 2022[703][704]. - The company is exposed to foreign currency exchange risk from contracts with vendors outside the U.S., but changes in exchange rates did not materially impact financial results for the years ended December 31, 2024, 2023, and 2022[705][706].